目的 調(diào)查分析2011-2015年唐山市傳染病醫(yī)院核苷類抗肝炎病毒藥物的使用情況，為臨床合理用藥、藥品采購提供參考。方法 回顧性分析2011-2015年唐山市傳染病醫(yī)院核苷類抗肝炎病毒藥物使用信息，采用Microsoft Excel 2000統(tǒng)計分析方法，計算各類藥物的銷售金額、用藥頻度（DDDs）值及其排序、日均費用（DDC）值及其排序和藥品排序比（B/A）值。結(jié)果 2011-2015年唐山市傳染病醫(yī)院核苷類抗肝炎病毒藥物銷售金額逐年增加，拉米夫定、阿德福韋酯和恩替卡韋銷售額最大，三者銷售額之和超過總銷售額的90%。但是銷售額構(gòu)成比和DDDs排序變化趨勢有所不同，拉米夫定和阿德福韋酯的銷售金額構(gòu)成比和DDDs排序呈下降趨勢，而恩替卡韋呈上升趨勢。富馬酸替諾福韋二吡呋酯DDC值較大（DDC>100），阿德福韋酯的DDC值較?。―DC<10），5種藥物的DDC均有所下降，其中富馬酸替諾福韋二吡呋酯的DDC下降最顯著，阿德福韋酯的DDC下降最小。各種核苷類抗肝炎病毒藥物B/A值大部分接近1。結(jié)論 唐山市傳染病醫(yī)院核苷類抗肝炎病毒藥物的用藥金額呈增長趨勢，臨床使用日趨合理，但也存在個別藥品日均費用較高、同步性較差的問題，需進(jìn)一步加強管理。

Objective To investigate and analyze the usage of anti hepatitis virus nucleoside drugs in Tangshan Infectious Disease Hospital from 2011 to 2015, to provide reference for the clinically rational use of drugs and drug procurement. Methods The drug outbound data in Tangshan Infectious Disease Hospital from 2011 to 2015 were collected, and the Microsoft Excel 2000 software was used for statistical analysis. The consumption sum, defined daily doses (DDDs), defined daily cost (DDC), sequences, and drug sequence ratio (B/A) were analyzed statistically. Results The sale amounts of anti hepatitis virus nucleoside drugs in Tangshan Infectious Disease Hospital increased year by year from 2011 to 2015. The sales of lamivudine, adefovir, and entecavir were all over 90% of total sales in five years. But the trend of sales composition ratio and DDDs sort were different, the trend of sales composition ratio and DDDs sort of lamivudine and adefovir decresed, butthose of entecavir increased. The DDC of tenofovir disoproxil fumarate was maximum (DDC>100), DDC of adefovir was minimum (DDC<10). DDC of all five kinds of drugs were decreased, tenofovir disoproxil fumarate of DDC decreased significantly, and those of adefovir dipivoxil had small decline. B/A values of all anti hepatitis virus nucleoside drugs were closed to 1. Conclusion The sale amounts of of anti hepatitis virus nucleoside drugs in Tangshan Infectious Disease Hospital show a rising trend, and clinical use is becoming more and more reasonable. However, the problem of high average daily cost and poor synchronism of few drugs are still existed, which needs further efforts to strengthen the management.